Desonide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Desonide: Low-potency topical corticosteroid → polyp of vocal cord
One-Sentence Summary
Desonide is a low-potency topical corticosteroid marketed in Canada as single-ingredient products. The TxGNN model predicts it may be relevant to polyp of vocal cord, with a score of 0.9991. There are currently 0 clinical trials and 0 publications supporting this prediction, so it rests on the model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | polyp of vocal cord |
| TxGNN Prediction Score | 0.9991 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available. Desonide is a low-potency topical corticosteroid with anti-inflammatory activity. Vocal cord polyps are often associated with chronic inflammation and edema, so a glucocorticoid effect is plausible in principle.
However, the available desonide formulations are topical dermatologic products (cream, ointment, lotion) and are not suited to delivery to the larynx. The link rests on the TxGNN prediction alone, with no clinical or literature support, and should be regarded as a hypothesis only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02229323 | PDP-DESONIDE | Not recorded | Not recorded |
| 02229315 | PDP-DESONIDE | Not recorded | Not recorded |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: No clinical trials or publications support this prediction, the mechanism of action data are missing, and the available topical formulations are not suited to laryngeal delivery. The evidence is limited to the model prediction (L5).
To proceed, the following is needed:
- Package insert warnings and contraindications from Health Canada
- Mechanism of action data
- Any preclinical or clinical studies of corticosteroids in vocal cord polyps
- An assessment of a suitable delivery route and formulation for the larynx
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.